About necitumumab
EGFR-targeted monoclonal antibody
Used for
- With gemcitabine and cisplatin for advanced squamous non-small-cell lung cancer.
Usual adult dose
800 mg by intravenous infusion on days 1 and 8 of each 21-day cycle, with chemotherapy.
Common side effects
- Skin rash
- Low magnesium and other electrolyte changes
- Blood clots
- Infusion reactions
Important warnings
- Can cause serious or fatal heart and lung arrest.
- Monitor electrolytes, especially magnesium, during treatment.
- Infusion reactions and severe skin reactions may occur.
- Blood clots can be serious or fatal.
Pregnancy
May harm an unborn baby; effective contraception is recommended during treatment and for three months afterward.
Breastfeeding
Avoid breastfeeding during treatment and for three months after the last dose.
Interactions
- No clinically significant drug interactions are established.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.